Modulation of Glucocorticoid Action and the Treatment of Type-2 Diabetes

The document from 2007 explores the potential of targeting glucocorticoid (GC) action to treat type-2 diabetes, obesity, and metabolic syndrome. It reviews the role of the enzyme 11β-HSD1 in amplifying local GC action and its implication in obesity and type-2 diabetes. Studies have shown that selective 11β-HSD1 inhibitors can improve insulin sensitivity and lipid profiles in rodents, and glucocorticoid receptor antagonists have also been found to improve insulin sensitivity and reduce glucose production. However, the efficacy of these strategies in humans remains to be tested in clinical trials. The document emphasizes the need for such trials to evaluate the potential of GC modulation as a treatment for type-2 diabetes.